Search Within

Matthew J Matasar

  1. "2018"
  2. "Survivorship Research"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Lymphoma (16)
  5. Survivorship Research (16)
  6. Biostatistics Service (10)

More Groups

People
  1. Craig Moskowitz (8)
  2. Craig Sauter (6)
  3. Anas Younes (5)
  4. Andrew Zelenetz (5)
  5. Anita Kumar (5)
  6. Paul Hamlin (5)

More People

Years
  1. 2018 (16)
Publications
  1. Blood (6)
  2. Biology of Blood and Marrow Transplantation (4)
  3. Journal of Clinical Oncology (2)
  4. Blood Advances (1)
  5. Blood Cancer Journal (1)
  6. Cancer (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Elsevier Inc. (4)
  3. American Society of Clinical Oncology (2)
  4. Elsevier Science, Inc. (1)
  5. Nature Publishing Group (1)
  6. Wiley Blackwell (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study
    Meeting Abstract

    Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; McMillan, A.; Ozcan, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study
    Meeting Abstract

    Budde, L. E.; Sehn, L. H.; Assouline, S.; Flinn, I. W.; Isufi, I.; Yoon, S. S.; Kim, W. S.; Matasar, M. J.; Nastoupil, L. J.; Santiago, R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
    Journal Article

    Kumar, A.; Vardhana, S.; Moskowitz, A. J.; Porcu, P.; Dogan, A.; Dubovsky, J. A.; Matasar, M. J.; Zhang, Z.; Younes, A.; Horwitz, S. M.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Impact of pre-transplant rituximab on efficacy of revaccination of lymphoma patients after autologous hematopoietic stem cell transplantation
    Meeting Abstract

    Preston, E. V.; Palazzo, M. A.; Seier, K.; Devlin, S. M.; Giralt, S.; Scordo, M.; Dahi, P. B.; Matasar, M. J.; Moskowitz, C. H.; Sauter, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in the United States
    Meeting Abstract

    Feliciano, J.; Mueller, K.; Korol, E. E.; He, Z.; Khan, N.; Matasar, M. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL
    Meeting Abstract

    Sehn, L. H.; Kamdar, M.; Herrera, A. F.; McMillan, A.; Flowers, C.; Kim, W. S.; Kim, T. M.; OĢˆzcan, M.; Demeter, J.; Hertzberg, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial
    Journal Article

    Parker, P. A.; Banerjee, S. C.; Matasar, M. J.; Bylund, C. L.; Rogers, M.; Franco, K.; Schofield, E.; Li, Y.; Levin, T. T.; Jacobsen, P. B.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Beyond maximum grade: Modernising the assessment and reporting of adverse events in haematological malignancies
    Journal Article

    Thanarajasingam, G.; Minasian, L. M.; Baron, F.; Cavalli, F.; De Claro, R. A.; Dueck, A. C.; El-Galaly, T. C.; Everest, N.; Geissler, J.; Gisselbrecht, C.; more...
    The Lancet Haematology (2018)

    Fulltext@MSK | Save